Posttranslational Modifications of Proteins in Type 1 Diabetes: The Next Step in Finding the Cure?

  1. Chantal Mathieu2
  1. 1Juvenile Diabetes Research Foundation, New York, New York
  2. 2Laboratory of Experimental Medicine and Endocrinology (LEGENDO), Catholic University Leuven, Leuven, Belgium
  3. 3Department of Biochemistry and Molecular Biology, The University of Melbourne, Melbourne, Victoria, Australia
  4. 4Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Victoria, Australia
  1. Corresponding author: Jessica L. Dunne, jdunne{at}jdrf.org.

Abstract

The overall role of modification of β-cell antigens in type 1 diabetes has not been elucidated and was the focus of a recent workshop on posttranslational modification of proteins in type 1 diabetes. The prevailing opinion of the workshop attendees was that novel insights into the mechanism of loss of immune tolerance might be gained and that novel diagnostic and therapeutic approaches could be developed for type 1 diabetes if protein modifications were shown to play a critical role in the disease.

  • Received November 30, 2011.
  • Accepted March 30, 2012.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

No Related Web Pages
| Table of Contents